HALO HALOZYME THERAPEUTICS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1159036 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY45.0%
TTM net income YoY-18.5%
TTM EPS YoY-15.6%
Revenue 3-yr CAGR32.2%
Net income 3-yr CAGR24.1%
Margins
Gross margin82.3%
Operating margin37.4%
Net margin26.9%
FCF margin49.1%
EBITDA margin38.3%
Returns
ROE216.4%
ROA17.0%
ROIC (approx.)26.6%
Asset turnover0.63x
Leverage & solvency
Liabilities / assets101.6%
Debt / equity—
Current ratio3.88x
Interest coverage30.58x
Cash quality & payout
Operating cash flow / net income1.85x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.40B | $1.02B |
| Cost of revenue | $228.77M | $159.42M |
| Gross profit | $1.17B | $855.91M |
| R&D expense | $81.49M | $79.05M |
| SG&A expense | $207.09M | $154.34M |
| Operating income | $469.01M | $551.48M |
| Interest expense | $18.13M | $18.09M |
| Pretax income | $466.88M | $557.13M |
| Income tax | $149.99M | $113.04M |
| Net income | $316.89M | $444.09M |
| EBITDA | $480.39M | $561.74M |
| EPS (basic) | 2.64 | 3.50 |
| EPS (diluted) | 2.56 | 3.43 |
| Weighted avg. shares (diluted) | 123.90M | 129.42M |
| Balance sheet | ||
| Cash & equivalents | $133.82M | $115.85M |
| Receivables | $426.27M | $288.20M |
| Inventory | $176.47M | $141.86M |
| Current assets | $825.21M | $1.09B |
| PP&E, net | $44.44M | $40.86M |
| Goodwill | $580.36M | $416.82M |
| Intangibles | $981.47M | $401.83M |
| Total assets | $2.53B | $2.06B |
| Current liabilities | $177.09M | $139.10M |
| Short-term debt | $0 | $0 |
| Long-term debt | $2.14B | $1.51B |
| Total debt | $2.14B | $1.51B |
| Total liabilities | $2.48B | $1.70B |
| Shareholders' equity | $48.81M | $363.82M |
| Net debt | $2.01B | $1.39B |
| Shares outstanding | 117.78M | 123.14M |
| Cash flow statement | ||
| Operating cash flow | $651.56M | $479.06M |
| Capital expenditure | $6.97M | $10.70M |
| Free cash flow | $644.59M | $468.37M |
| Investing cash flow | -$545.81M | -$262.72M |
| Financing cash flow | -$85.17M | -$218.86M |
| Depreciation & amortization | $11.39M | $10.26M |
| Stock-based compensation | $51.56M | $43.38M |
| Share buybacks | $342.37M | $250.00M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.